Peterse Elisabeth F P, van Leeuwen Thed N, Cleton-Jansen Anne-Marie
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Centre for Science and Technology Studies, Leiden University, Leiden, The Netherlands.
J Bone Oncol. 2017 Apr 7;7:29-31. doi: 10.1016/j.jbo.2017.04.004. eCollection 2017 Jun.
Osteosarcoma is a primary malignant bone tumour, for which no improvement in survival rate has been made since the nineteen seventies. We set out to systemically identify the studies performed in the past two decades describing potential future therapies. Strikingly, we obtained a total of 5282 PubMed hits on this subject. The amount of publications has increased almost exponentially over the past few years. Studies from Chinese institutes are mainly responsible for this huge increase, accounting for 53% of the publications in 2015. Approximately 1/3 of all drugs described in the past three years could be classified as traditional medicine. Furthermore, it struck our attention that even though in such studies multiple cell lines are essential to represent the heterogeneity in patients, many studies were performed with only one or two cell lines, U-2 OS or MG-63. These cells are fast growing, facilitating rapid experimental application but also boosting drug responsiveness. This probably explains why so many studies have been published for this relatively rare disease. Furthermore, it illustrates the current publication pressure, especially in China.
骨肉瘤是一种原发性恶性骨肿瘤，自20世纪70年代以来其生存率没有得到改善。我们着手系统地识别过去二十年中描述潜在未来治疗方法的研究。令人惊讶的是，我们在这个主题上总共获得了5282条来自PubMed的搜索结果。在过去几年里，出版物的数量几乎呈指数级增长。来自中国机构的研究是这一巨大增长的主要原因，占2015年出版物的53%。在过去三年中描述的所有药物中，约有三分之一可归类为传统药物。此外，我们注意到，尽管在这类研究中，多个细胞系对于代表患者的异质性至关重要，但许多研究仅使用一两个细胞系进行，即U-2 OS或MG-63。这些细胞生长迅速，便于快速进行实验应用，但也提高了药物反应性。这可能解释了为什么针对这种相对罕见的疾病发表了如此多的研究。此外，这也说明了当前的发表压力，尤其是在中国。
